ArticleThe Pediatric infectious disease journal2026
High Viral Suppression Rates and Attrition Rates Among Children With Perinatally Acquired HIV in the Thai National AIDS Program, 2023.
Article in The Pediatric infectious disease journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundEarly initiation of antiretroviral therapy (ART) can reduce HIV-related morbidity and mortality. We described treatment outcomes of children living with HIV identified through the early infant diagnosis (EID) program and linked to the Thai National AIDS Program (NAP).
methodsWe used the Thai NAP database to conduct a cohort analysis of infants identified through the EID program who initiated ART from August 2014 to July 2018, with data cutoff on 31 December 2023. The Thai NAP is a national database linked to public hospitals in Thailand and a vital status registry. First-line ART was a lopinavir/ritonavir-based regimen; pediatric dolutegravir became available in May 2023. Attrition outcomes included death and loss-to-follow-up (LTFU). Virologic suppression was defined as plasma HIV RNA <200 copies/mL. The overall 7-year survival rate was estimated using the Kaplan-Meier estimate.
resultsThe median [interquartile range (IQR)] age at ART initiation was 3.3 (2.2-6) months for the 230 infants included. Twenty children [8.7%, 95% confidence interval (CI): 5.4-13.1] died at a median (IQR) age of 1.1 (0.6-3.0) years. LTFU was 44 (19.1%, 95% CI: 14.3-24.8) at the median (IQR) age of 3.6 (2.0-5.6) years. Overall, the 7-year survival rate was 90.7% (95% CI: 85.6-94.1). Among 166 children retained on ART, the median (IQR) age at the last visit was 7.7 (6.7-8.7) years. Of these, 107 (64.5%) children transitioned to dolutegravir-based regimens. Overall, virologic suppression was achieved in 144 children at the last visit, representing 62.6% of children who initiated ART and 86.7% of children who remained in care.
conclusionsChildren diagnosed with HIV through EID and linked to the Thai NAP had promising 7-year survival rates but substantial LTFU. Strategies to improve retention and re-engagement in care and are essential for better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.